Ad
related to: repatha vs praluent pricegoodrx.com has been visited by 100K+ users in the past month
"About 50% of US physicians advise patients consult GoodRx." - Fortune
- GoodRx Gold® Membership
Do You Have Multiple Prescriptions?
Get Even Lower Prices as a Member.
- Research You Can Rely On
Our team works hard to provide you
with the latest healthcare info.
- Do I Need Insurance?
No! Compare Our Prices to Your
Insurance & Get the Biggest Savings
- GoodRx® & Medicare
Beat your Medicare Copay!
Discover More Savings Options Today
- GoodRx Gold® Membership
Search results
Results from the WOW.Com Content Network
Evolocumab, [6] sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia. Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) .
Repatha is a brand name for the injectable drug evolocumab. Repatha treats high cholesterol and reduces the risk of heart attack , stroke, and certain types of heart surgery in adults with ...
Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.
Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors , and it was the first such agent ...
TRENTON, N.J. (AP) — The maker of an expensive cholesterol drug is slashing the list price, which should make it more affordable for patients. Amgen slashes price of $14,000-a-year cholesterol ...
Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab.
In 2014, Amgen sued Sanofi for infringing Amgen's patents on antibodies that lower LDL cholesterol, sometimes called “bad” cholesterol. [2]Amgen held two patents for antibodies that bind to specific amino acids on PCSK9, a protein involved in regulating LDL cholesterol.
Drugs in the lawsuit are Regeneron's Praluent (alirocumab) and Amgen's Repatha (evolocumab). In May, Regeneron filed an antitrust suit that alleged Amgen conducted a bundling scheme that allowed ...